Amneal Pharmaceuticals submits ANDA to FDA for three key complex generics

Amneal Pharmaceuticals announced it has submitted Abbreviated New Drug Applications to the U.S. Food and Drug Administration for three key complex generic products, including: IQVIA, Albuterol sulfate inhalation Bimatoprost ophthalmic solution, Propofol emulsion ..”We continue to make excellent progress advancing our pipeline of complex, high-value medicines. The filing of applications for three new complex generics are additional proof points in our successful innovation journey. Today, about 90% of our generics R&D pipeline is made up of complex products. As we move up the value chain of product complexity, we are adding new and sustainable long-term growth drivers to our diversified portfolio,” said Chirag and Chintu Patel, Co-Chief Executive Officers.